Freeline Therapeutics could reduce bleeding risk for haemophilia patients

For the paper, published in the New England Journal of Medicine, experts from UCL, Royal Free Hospital and biotechnology company Freeline Therapeutics trialled and continue to evaluate a new type of adeno-associated virus (AAV) gene therapy candidate, called FLT180a, to treat severe and moderately severe cases of the condition.

The Phase I/II trial was sponsored by UCL and funded by Freeline Therapeutics.

Read the full story here.

Related Content

We make UCL’s research physical and life sciences ideas happen.